Man Group
SCPH

Man Group’s scPharmaceuticals SCPH Stock Holding History

Man Group’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,430
Closed -$150K – 1930
2022
Q4 		$146K Buy
+20,430
New +$125K ﹤0.01% 1831

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Man Group's SCPH Position: Q1 2023 in Review

Man Group sold out of scPharmaceuticals (SCPH) in Q1 2023, closing a stake of 20,430 shares — an estimated $150K sold.

Man Group first reported a position in SCPH in Q4 2022 and held it in 1 quarter. The position peaked at $146K in Q4 2022. 62 funds tracked by Wall St. Rank hold SCPH as of Q1 2023.

  • Man Group reported no remaining scPharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 20,430 scPharmaceuticals shares in Q1 2023, an estimated $150K.
  • Man Group first reported a position in scPharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Man Group's scPharmaceuticals position peaked at $146K in Q4 2022.
  • 62 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.